Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Common Equity (2016 - 2025)

Integra Lifesciences Holdings' Common Equity history spans 17 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 32.47% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 32.47%, while the annual FY2025 figure was $1.0 billion, 32.47% down from the prior year.
  • Common Equity for Q4 2025 was $1.0 billion at Integra Lifesciences Holdings, up from $1.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.8 billion in Q4 2022 and bottomed at $1.0 billion in Q3 2025.
  • The 5-year median for Common Equity is $1.6 billion (2023), against an average of $1.5 billion.
  • The largest annual shift saw Common Equity increased 16.74% in 2021 before it plummeted 32.47% in 2025.
  • A 5-year view of Common Equity shows it stood at $1.7 billion in 2021, then increased by 7.1% to $1.8 billion in 2022, then fell by 12.0% to $1.6 billion in 2023, then dropped by 2.68% to $1.5 billion in 2024, then tumbled by 32.47% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Common Equity are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).